Advanced search

Vol 75, No 4 (2024)
Guidelines / Expert consensus
Published online: 2024-08-19

open access

View PDF (Polish) Download PDF file
Page views 1561
Article views/downloads 1054
Get Citation

Connect on Social Media

Connect on Social Media

Erratum has been published: #1
The content of this article is also available in the following languages:
English

Polish diagnostic and therapeutic recommendations for adrenocortical carcinoma

Daria Handkiewicz-Junak1, Marek Dedecjus2, Urszula Ambroziak3, Marcin Barczyński4, Lucyna Bednarek-Papierska5, Ewa Chmielik1, Andrzej Cichocki2, Agnieszka Czarniecka1, Jarosław Ćwikła6, Kornelia Hasse-Lazar1, Alicja Hubalewska-Dydejczyk4, Joanna Januszkiewicz-Caulier2, Barbara Jarząb1, Grzegorz Kamiński7, Małgorzata Karbownik-Lewińska89, Agnieszka Kolasińska-Ćwikła2, Łukasz Koperski3, Beata Kos-Kudła10, Agnieszka Kotecka-Blicharz1, Aldona Kowalska1112, Jolanta Krajewska1, Leszek Królicki3, Andrzej Lewiński89, Iwona Michałowska13, Małgorzata Oczko-Wojciechowska1, Marek Ruchała14, Anhelli Syrenicz15, Andrzej Tysarowski2, Barbara Ziółkowska1, Agnieszka Żyłka2
DOI: 10.5603/ep.101677
Pubmed: 39279304
Endokrynol Pol 2024;75(4):339-358.

Abstract

Advances in the diagnosis and treatment of adrenocortical carcinoma (ACC), along with the development of new therapeutic and diagnostic methods, have prompted a team of experts to formulate the first Polish guidelines for managing ACC.

This article presents the diagnostic and therapeutic recommendations resulting from the discussion of specialists from various medical specialities, who participated in a series of online meetings aimed at developing consistent and effective recommendations under the National Oncology Strategy.

These guidelines aim to optimise ACC treatment in Poland through coordinated efforts of multidisciplinary specialist teams, ensuring an effective and modern approach. 

Keywords: adrenocortical carcinomaadrenal glandcarcinomacancerdiagnostic recommendationstherapeutic recommendations

Article available in PDF format

View PDF (Polish) Download PDF file

References

  1. Benson III AB, Berman Z, Blaszkowsky LS, Brock P, Chan J, Center sCancer, et al. NCCN Guidelines Version 1.2024 Neuroendocrine and Adrenal Tumors NCCN Guidelines Panel Disclosures. 2024. https://www.nccn.org/home/member-.
  2. Fassnacht M, Assie G, Baudin E, et al. ESMO Guidelines Committee. Electronic address: clinicalguidelines@esmo.org. Adrenocortical carcinomas and malignant phaeochromocytomas: ESMO-EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2020; 31(11): 1476–1490.
    CrossRefPubMed
  3. Fassnacht M, Arlt W, Bancos I, et al. Management of adrenal incidentalomas: European Society of Endocrinology Clinical Practice Guideline in collaboration with the European Network for the Study of Adrenal Tumors. Eur J Endocrinol. 2016; 175(2): G1–G34.
    CrossRefPubMed
  4. Fassnacht M, Dekkers O, Else T, et al. European Society of Endocrinology Clinical Practice Guidelines on the management of adrenocortical carcinoma in adults, in collaboration with the European Network for the Study of Adrenal Tumors. Eur J Endocrinol. 2018; 179(4): G1–G46.
    CrossRefPubMed
  5. Bednarczuk T, Bolanowski M, Sworczak K, et al. Adrenal incidentaloma in adults — management recommendations by the Polish Society of Endocrinology. Endokrynol Pol. 2016; 67(2): 234–258.
    CrossRefPubMed
  6. Schwarte S, Brabant EG, Bastian L, et al. Cortisol as a possible marker of metastatic adrenocortical carcinoma: a case report with 3-year follow-up. Anticancer Res. 2007; 27(4A): 1917–1920.
    PubMed
  7. Januszewicz A, Januszewicz W, Jarząb B, et al. Grupa Robocza Polskiego Towarzystwa Nadciśnienia Tętniczego. Wytyczne dotyczące diagnostyki i leczenia chorych z guzem chromochłonnym [Diagnosis and management of patients with pheochromocytoma]. Nadciśnienie Tętn. 2006; 10(1): 1–19.
  8. Viëtor CL, Creemers SG, van Kemenade FJ, et al. How to Differentiate Benign from Malignant Adrenocortical Tumors? Cancers (Basel). 2021; 13(17).
    CrossRefPubMed
  9. Fleseriu M. Salivary Cortisol in the Diagnosis of Cushing Syndrome, Always More Than One! J Endocr Soc. 2020; 4(10): bvaa109.
    CrossRefPubMed
  10. Funder JW, Carey RM, Mantero F, et al. The Management of Primary Aldosteronism: Case Detection, Diagnosis, and Treatment: An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab. 2016; 101(5): 1889–1916.
    CrossRefPubMed
  11. Sasano H, Suzuki T, Moriya T. Recent advances in histopathology and immunohistochemistry of adrenocortical carcinoma. Endocr Pathol. 2006; 17(4): 345–354.
    CrossRefPubMed
  12. Suzuki S, Minamidate T, Shiga A, et al. Steroid metabolites for diagnosing and predicting clinicopathological features in cortisol-producing adrenocortical carcinoma. BMC Endocr Disord. 2020; 20(1): 173.
    CrossRefPubMed
  13. Bancos I, Taylor AE, Chortis V, et al. ENSAT EURINE-ACT Investigators. Urine steroid metabolomics for the differential diagnosis of adrenal incidentalomas in the EURINE-ACT study: a prospective test validation study. Lancet Diabetes Endocrinol. 2020; 8(9): 773–781.
    CrossRefPubMed
  14. Berke K, Constantinescu G, Masjkur J, et al. Plasma Steroid Profiling in Patients With Adrenal Incidentaloma. J Clin Endocrinol Metab. 2022; 107(3): e1181–e1192.
    CrossRefPubMed
  15. Vogg N, Müller T, Floren A, et al. Simplified urinary steroid profiling by LC-MS as diagnostic tool for malignancy in adrenocortical tumors. Clin Chim Acta. 2023; 543: 117301.
    CrossRefPubMed
  16. Chortis V, Bancos I, Nijman T, et al. Urine Steroid Metabolomics as a Novel Tool for Detection of Recurrent Adrenocortical Carcinoma. J Clin Endocrinol Metab. 2020; 105(3): e307–e318.
    CrossRefPubMed
  17. Hamblin R, Coulden A, Fountas A, et al. The diagnosis and management of Cushing's syndrome in pregnancy. J Neuroendocrinol. 2022; 34(8): e13118.
    CrossRefPubMed
  18. Ambroziak U, Kondracka A, Bartoszewicz Z, et al. The morning and late-night salivary cortisol ranges for healthy women may be used in pregnancy. Clin Endocrinol (Oxf). 2015; 83(6): 774–778.
    CrossRefPubMed
  19. Savas M, Mehta S, Agrawal N, et al. Approach to the Patient: Diagnosis of Cushing Syndrome. J Clin Endocrinol Metab. 2022; 107(11): 3162–3174.
    CrossRefPubMed
  20. Forestiero V, Sconfienza E, Mulatero P, et al. Primary aldosteronism in pregnancy. Rev Endocr Metab Disord. 2023; 24(1): 39–48.
    CrossRefPubMed
  21. Else T. Association of adrenocortical carcinoma with familial cancer susceptibility syndromes. Mol Cell Endocrinol. 2012; 351(1): 66–70.
    CrossRefPubMed
  22. Gonzalez KD, Noltner KA, Buzin CH, et al. Beyond Li Fraumeni Syndrome: clinical characteristics of families with p53 germline mutations. J Clin Oncol. 2009; 27(8): 1250–1256.
    CrossRefPubMed
  23. Raymond VM, Else T, Everett JN, et al. Prevalence of germline TP53 mutations in a prospective series of unselected patients with adrenocortical carcinoma. J Clin Endocrinol Metab. 2013; 98(1): E119–E125.
    CrossRefPubMed
  24. Renaux-Petel M, Charbonnier F, Théry JC, et al. Contribution of de novo and mosaic mutations to Li-Fraumeni syndrome. J Med Genet. 2018; 55(3): 173–180.
    CrossRefPubMed
  25. Domènech M, Grau E, Solanes A, et al. Characteristics of Adrenocortical Carcinoma Associated With Lynch Syndrome. J Clin Endocrinol Metab. 2021; 106(2): 318–325.
    CrossRefPubMed
  26. Gatta-Cherifi B, Chabre O, Murat A, et al. Adrenal involvement in MEN1. Analysis of 715 cases from the Groupe d'etude des Tumeurs Endocrines database. Eur J Endocrinol. 2012; 166(2): 269–279.
    CrossRefPubMed
  27. Peppercorn PD, Grossman AB, Reznek RH. Imaging of incidentally discovered adrenal masses. Clin Endocrinol (Oxf). 1998; 48(4): 379–388.
    CrossRefPubMed
  28. Caoili EM, Korobkin M, Francis IR, et al. Adrenal masses: characterization with combined unenhanced and delayed enhanced CT. Radiology. 2002; 222(3): 629–633.
    CrossRefPubMed
  29. Ilias I, Sahdev A, Reznek RH, et al. The optimal imaging of adrenal tumours: a comparison of different methods. Endocr Relat Cancer. 2007; 14(3): 587–599.
    CrossRefPubMed
  30. Mackie GC, Shulkin BL, Ribeiro RC, et al. Use of [18F]fluorodeoxyglucose positron emission tomography in evaluating locally recurrent and metastatic adrenocortical carcinoma. J Clin Endocrinol Metab. 2006; 91(7): 2665–2671.
    CrossRefPubMed
  31. Groussin L, Bonardel G, Silvéra S, et al. 18F-Fluorodeoxyglucose positron emission tomography for the diagnosis of adrenocortical tumors: a prospective study in 77 operated patients. J Clin Endocrinol Metab. 2009; 94(5): 1713–1722.
    CrossRefPubMed
  32. Deandreis D, Leboulleux S, Caramella C, et al. FDG PET in the management of patients with adrenal masses and adrenocortical carcinoma. Horm Cancer. 2011; 2(6): 354–362.
    CrossRefPubMed
  33. Petersenn S, Richter PA, Broemel T, et al. German ACC Study Group. Computed tomography criteria for discrimination of adrenal adenomas and adrenocortical carcinomas: analysis of the German ACC registry. Eur J Endocrinol. 2015; 172(4): 415–422.
    CrossRefPubMed
  34. Cistaro A, Niccoli Asabella A, Coppolino P, et al. Diagnostic and prognostic value of 18F-FDG PET/CT in comparison with morphological imaging in primary adrenal gland malignancies - a multicenter experience. Hell J Nucl Med. 2015; 18(2): 97–102.
    CrossRefPubMed
  35. Nakajo M, Jinguji M, Nakajo M, et al. Texture analysis of FDG PET/CT for differentiating between FDG-avid benign and metastatic adrenal tumors: efficacy of combining SUV and texture parameters. Abdom Radiol (NY). 2017; 42(12): 2882–2889.
    CrossRefPubMed
  36. Guerin C, Pattou F, Brunaud L, et al. Performance of 18F-FDG PET/CT in the Characterization of Adrenal Masses in Noncancer Patients: A Prospective Study. J Clin Endocrinol Metab. 2017; 102(7): 2465–2472.
    CrossRefPubMed
  37. Corwin MT, Navarro SM, Malik DG, et al. Differences in Growth Rate on CT of Adrenal Adenomas and Malignant Adrenal Nodules. AJR Am J Roentgenol. 2019; 213(3): 632–636.
    CrossRefPubMed
  38. Ahmed AA, Thomas AJ, Ganeshan DM, et al. Adrenal cortical carcinoma: pathology, genomics, prognosis, imaging features, and mimics with impact on management. Abdom Radiol (NY). 2020; 45(4): 945–963.
    CrossRefPubMed
  39. Mayo-Smith WW, Song JH, Boland GL, et al. Management of Incidental Adrenal Masses: A White Paper of the ACR Incidental Findings Committee. J Am Coll Radiol. 2017; 14(8): 1038–1044.
    CrossRefPubMed
  40. Aubert S, Wacrenier A, Leroy X, et al. Weiss system revisited: a clinicopathologic and immunohistochemical study of 49 adrenocortical tumors. Am J Surg Pathol. 2002; 26(12): 1612–1619.
    CrossRefPubMed
  41. Bisceglia M, Ludovico O, Di Mattia A, et al. Adrenocortical oncocytic tumors: report of 10 cases and review of the literature. Int J Surg Pathol. 2004; 12(3): 231–243.
    CrossRefPubMed
  42. Sinclair TJ, Gillis A, Alobuia WM, et al. Surgery for adrenocortical carcinoma: When and how? Best Pract Res Clin Endocrinol Metab. 2020; 34(3): 101408.
    CrossRefPubMed
  43. Nilubol N, Patel D, Kebebew E. Does Lymphadenectomy Improve Survival in Patients with Adrenocortical Carcinoma? A Population-Based Study. World J Surg. 2016; 40(3): 697–705.
    CrossRefPubMed
  44. Reibetanz J, Jurowich C, Erdogan I, et al. German ACC study group. Impact of lymphadenectomy on the oncologic outcome of patients with adrenocortical carcinoma. Ann Surg. 2012; 255(2): 363–369.
    CrossRefPubMed
  45. Gerry JM, Tran TB, Postlewait LM, et al. Lymphadenectomy for Adrenocortical Carcinoma: Is There a Therapeutic Benefit? Ann Surg Oncol. 2016; 23(Suppl 5): 708–713.
    CrossRefPubMed
  46. Reibetanz J, Rinn B, Kunz AS, et al. Patterns of Lymph Node Recurrence in Adrenocortical Carcinoma: Possible Implications for Primary Surgical Treatment. Ann Surg Oncol. 2019; 26(2): 531–538.
    CrossRefPubMed
  47. Zsippai A, Szabó DR, Tömböl Z, et al. Effects of mitotane on gene expression in the adrenocortical cell line NCI-H295R: a microarray study. Pharmacogenomics. 2012; 13(12): 1351–1361.
    CrossRefPubMed
  48. Puglisi S, Calabrese A, Basile V, et al. New perspectives for mitotane treatment of adrenocortical carcinoma. Best Pract Res Clin Endocrinol Metab. 2020; 34(3): 101415.
    CrossRefPubMed
  49. Baudin E, Pellegriti G, Bonnay M, et al. Impact of monitoring plasma 1,1-dichlorodiphenildichloroethane (o,p'DDD) levels on the treatment of patients with adrenocortical carcinoma. Cancer. 2001; 92(6): 1385–1392, doi: 10.1002/1097-0142(20010915)92:6<1385::aid-cncr1461>3.0.co;2-2.
    PubMed
  50. Russo M, Scollo C, Pellegriti G, et al. Mitotane treatment in patients with adrenocortical cancer causes central hypothyroidism. Clin Endocrinol (Oxf). 2016; 84(4): 614–619.
    CrossRefPubMed
  51. Chortis V, Taylor AE, Schneider P, et al. Mitotane therapy in adrenocortical cancer induces CYP3A4 and inhibits 5α-reductase, explaining the need for personalized glucocorticoid and androgen replacement. J Clin Endocrinol Metab. 2013; 98(1): 161–171.
    CrossRefPubMed
  52. Kroiss M, Quinkler M, Lutz WK, et al. Drug interactions with mitotane by induction of CYP3A4 metabolism in the clinical management of adrenocortical carcinoma. Clin Endocrinol (Oxf). 2011; 75(5): 585–591.
    CrossRefPubMed
  53. Fassnacht M, Libé R, Kroiss M, et al. Adrenocortical carcinoma: a clinician's update. Nat Rev Endocrinol. 2011; 7(6): 323–335.
    CrossRefPubMed
  54. Terzolo M, Angeli A, Fassnacht M, et al. Adjuvant mitotane treatment for adrenocortical carcinoma. N Engl J Med. 2007; 356(23): 2372–2380.
    CrossRefPubMed
  55. Berruti A, Grisanti S, Pulzer A, et al. Long-Term Outcomes of Adjuvant Mitotane Therapy in Patients With Radically Resected Adrenocortical Carcinoma. J Clin Endocrinol Metab. 2017; 102(4): 1358–1365.
    CrossRefPubMed
  56. Terzolo M, Fassnacht M, Perotti P, et al. Adjuvant mitotane versus surveillance in low-grade, localised adrenocortical carcinoma (ADIUVO): an international, multicentre, open-label, randomised, phase 3 trial and observational study. Lancet Diabetes Endocrinol. 2023; 11(10): 720–730.
    CrossRefPubMed
  57. Nelson DW, Chang SC, Bandera BC, et al. Adjuvant Radiation is Associated with Improved Survival for Select Patients with Non-metastatic Adrenocortical Carcinoma. Ann Surg Oncol. 2018; 25(7): 2060–2066.
    CrossRefPubMed
  58. Wu K, Liu Xu, Liu Z, et al. Benefit of Postoperative Radiotherapy for Patients With Nonmetastatic Adrenocortical Carcinoma: A Population-Based Analysis. J Natl Compr Canc Netw. 2021; 19(12): 1425–1432.
    CrossRefPubMed
  59. Baudin E, Leboulleux S, Al Ghuzlan A, et al. Therapeutic management of advanced adrenocortical carcinoma: what do we know in 2011? Horm Cancer. 2011; 2(6): 363–371.
    CrossRefPubMed
  60. Hermsen IGC, Gelderblom H, Kievit J, et al. Extremely long survival in six patients despite recurrent and metastatic adrenal carcinoma. Eur J Endocrinol. 2008; 158(6): 911–919.
    CrossRefPubMed
  61. Libé R, Borget I, Ronchi CL, et al. ENSAT network. Prognostic factors in stage III-IV adrenocortical carcinomas (ACC): an European Network for the Study of Adrenal Tumor (ENSAT) study. Ann Oncol. 2015; 26(10): 2119–2125.
    CrossRefPubMed
  62. Megerle F, Herrmann W, Schloetelburg W, et al. German ACC Study Group. Mitotane Monotherapy in Patients With Advanced Adrenocortical Carcinoma. J Clin Endocrinol Metab. 2018; 103(4): 1686–1695.
    CrossRefPubMed
  63. Reidy-Lagunes DL, Lung B, Untch BR, et al. Complete Responses to Mitotane in Metastatic Adrenocortical Carcinoma-A New Look at an Old Drug. Oncologist. 2017; 22(9): 1102–1106.
    CrossRefPubMed
  64. Vezzosi D, Do Cao C, Hescot S, et al. For Comete-Cancer Network. Time Until Partial Response in Metastatic Adrenocortical Carcinoma Long-Term Survivors. Horm Cancer. 2018; 9(1): 62–69.
    CrossRefPubMed
  65. Fassnacht M, Terzolo M, Allolio B, et al. FIRM-ACT Study Group. Combination chemotherapy in advanced adrenocortical carcinoma. N Engl J Med. 2012; 366(23): 2189–2197.
    CrossRefPubMed
  66. Bukowski RM, Wolfe M, Levine HS, et al. Phase II trial of mitotane and cisplatin in patients with adrenal carcinoma: a Southwest Oncology Group study. J Clin Oncol. 1993; 11(1): 161–165.
    CrossRefPubMed
  67. Williamson SK, Lew D, Miller GJ, et al. Phase II evaluation of cisplatin and etoposide followed by mitotane at disease progression in patients with locally advanced or metastatic adrenocortical carcinoma: a Southwest Oncology Group Study. Cancer. 2000; 88(5): 1159–1165.
    PubMed
  68. Kimpel O, Schindler P, Schmidt-Pennington L, et al. Efficacy and safety of radiation therapy in advanced adrenocortical carcinoma. Br J Cancer. 2023; 128(4): 586–593.
    CrossRefPubMed
  69. Sperone P, Ferrero A, Daffara F, et al. Gemcitabine plus metronomic 5-fluorouracil or capecitabine as a second-/third-line chemotherapy in advanced adrenocortical carcinoma: a multicenter phase II study. Endocr Relat Cancer. 2010; 17(2): 445–453.
    CrossRefPubMed
  70. Henning JEK, Deutschbein T, Altieri B, et al. Gemcitabine-Based Chemotherapy in Adrenocortical Carcinoma: A Multicenter Study of Efficacy and Predictive Factors. J Clin Endocrinol Metab. 2017; 102(11): 4323–4332.
    CrossRefPubMed
  71. Cosentini D, Badalamenti G, Grisanti S, et al. Activity and safety of temozolomide in advanced adrenocortical carcinoma patients. Eur J Endocrinol. 2019; 181(6): 681–689.
    CrossRefPubMed
  72. Campbell MT, Jimenez C, Long JP, et al. 1MO An open-label, phase II trial of cabozantinib for advanced adrenocortical carcinoma. Ann Oncol. 2022; 33: S545.
    CrossRef
  73. Kroiss M, Megerle F, Kurlbaum M, et al. Objective Response and Prolonged Disease Control of Advanced Adrenocortical Carcinoma with Cabozantinib. J Clin Endocrinol Metab. 2020; 105(5): 1461–1468.
    CrossRefPubMed
  74. Burotto M, Tageja N, Rosenberg A, et al. Brain metastasis in patients with adrenocortical carcinoma: a clinical series. J Clin Endocrinol Metab. 2015; 100(2): 331–336.
    CrossRefPubMed

About cookies

Necessary cookies

Allways active

These cookies are necessary for the proper display and operation of the website. Blocking them may cause the website to malfunction.

Analytical cookies

As part of our website, we use analytical tools, such as Google Analytics, that allow us to verify website traffic. These tools may require the use of cookies.

Community cookies

These are cookies associated with the social networks we use. Accepting them will allow us to associate your visit to the site with our social media profiles.

Marketing cookies

These are cookies responsible for carrying out advertising and marketing activities - consenting to their use will allow us to target you with advertisements based on your previous activities within our website.

Copyright © 2023-2024 Via Medica Regulations Cookie policy Privacy Statement Legal Note